DOSINDYGO -DOSe finding for INtraoperative ...
Document type :
Autre communication scientifique (congrès sans actes - poster - séminaire...): Communication dans un congrès avec actes
Title :
DOSINDYGO -DOSe finding for INtraoperative photoDYnamic therapy of GliOblastoma
Author(s) :
Dupont, C. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Lecomte, F. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Deleporte, P. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Baert, G [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Mordon, Serge [Auteur]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Faculté de Médecine Henri Warembourg - Université de Lille
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Reyns, N. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Vermandel, M. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Lecomte, F. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Deleporte, P. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Baert, G [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Mordon, Serge [Auteur]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Faculté de Médecine Henri Warembourg - Université de Lille
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Reyns, N. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Vermandel, M. [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Conference title :
17th International Photodynamic Association World Congress
City :
Cambridge, Massachusetts
Country :
Etats-Unis d'Amérique
Start date of the conference :
2019-06-28
English keyword(s) :
photodynamic therapy
glioblastoma
clinical trial
light dose escalation
glioblastoma
clinical trial
light dose escalation
HAL domain(s) :
Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Ingénierie biomédicale
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Ingénierie biomédicale
English abstract : [en]
Glioblastoma is a malignant brain tumor with a poor prognosis. Currently, complete resection is rarely feasible, since tumor cells usually infiltrate the surrounding brain. Recently, the INDYGO clinical trial has been ...
Show more >Glioblastoma is a malignant brain tumor with a poor prognosis. Currently, complete resection is rarely feasible, since tumor cells usually infiltrate the surrounding brain. Recently, the INDYGO clinical trial has been achieved to assess the toxicity of photodynamic therapy (PDT) delivered intraoperatively to treat newly diagnosed glioblastoma. Today, we believe that the PDT effect obtained in the INDYGO clinical trial can be improved by a higher light dose. The DOSINDYGO clinical trial aims to achieve a light-dose escalation increasing up to four times the initial light dose used in the INDYGO trial. An increase of both light power and treatment time should allow to treat deeper in the surrounding tissues (up to 8mm) and thus decrease the recurrence risk. First light dose will be reached by doubling the treatment time used in the INDYGO trial, the other one will be achieved by increasing light power only. This methodology was chosen in order to maintain an acceptable treatment time for anesthesia but also to prevent higher fluence rate that could induce a lower tolerance as observed in our preclinical results. Primary endpoint will be to determine the optimum light-dose regarding the ratio efficacy and tolerance of the treatment. Primary criterion is the assessment of the progression free survival within the bed border's cavity. Finally, although no adverse effect has been noticed during the INDYGO trial, increasing light dose in this DOSINDYGO trial could result in other direct and indirect biological effects.Show less >
Show more >Glioblastoma is a malignant brain tumor with a poor prognosis. Currently, complete resection is rarely feasible, since tumor cells usually infiltrate the surrounding brain. Recently, the INDYGO clinical trial has been achieved to assess the toxicity of photodynamic therapy (PDT) delivered intraoperatively to treat newly diagnosed glioblastoma. Today, we believe that the PDT effect obtained in the INDYGO clinical trial can be improved by a higher light dose. The DOSINDYGO clinical trial aims to achieve a light-dose escalation increasing up to four times the initial light dose used in the INDYGO trial. An increase of both light power and treatment time should allow to treat deeper in the surrounding tissues (up to 8mm) and thus decrease the recurrence risk. First light dose will be reached by doubling the treatment time used in the INDYGO trial, the other one will be achieved by increasing light power only. This methodology was chosen in order to maintain an acceptable treatment time for anesthesia but also to prevent higher fluence rate that could induce a lower tolerance as observed in our preclinical results. Primary endpoint will be to determine the optimum light-dose regarding the ratio efficacy and tolerance of the treatment. Primary criterion is the assessment of the progression free survival within the bed border's cavity. Finally, although no adverse effect has been noticed during the INDYGO trial, increasing light dose in this DOSINDYGO trial could result in other direct and indirect biological effects.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Source :
Files
- https://hal.archives-ouvertes.fr/hal-02879194/document
- Open access
- Access the document
- https://hal.archives-ouvertes.fr/hal-02879194/document
- Open access
- Access the document
- document
- Open access
- Access the document
- DOSINDYGO%20%E2%80%93%20DOSe%20finding%20for%20INtraoperative%20photoDYnamic%20therapy%20of%20GliOblastoma.pdf
- Open access
- Access the document